Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...

While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated the company’s willingness to protect Stelara, its branded anti-interleukin (IL)-12/23 biologic, against sales erosion from ...

Vigorous protection of Stelara’s position aligns with a strategy to grow in the immunology space. Credit: josefkubes via Shutterstock. During its presentation at the JP Morgan Healthcare Conference ...

Formycon (FSE: FYB) and its commercialization partner, fellow German firm Fresenius Kabi, have received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Otulfi ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...

Much has changed since we last checked in on potential rosters for the 2025 NBA All-Star Game in San Francisco a little more than a month ago. Unfortunately, injuries have taken some stars who ...

No clinically meaningful differences were observed in the efficacy, safety, pharmacokinetics, and immunogenicity of proposed biosimilar and ustekinumab for the treatment of moderate to severe plaque ...